
BioAge
@bioagelabs
BioAge is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases.
ID: 3406128460
http://www.bioagelabs.com 06-08-2015 18:50:23
811 Tweet
5,5K Takipçi
0 Takip Edilen



Today, our CEO Kristen Fortney is speaking at the 2025 Paul F. Glenn/AFAR Conference on the Biology of Aging, an annual meeting that brings together leading researchers advancing our understanding of aging biology and its therapeutic applications. Her talk, "From Human Data to


What if the secret to treating metabolic diseases lies in understanding why some people age more successfully than others? Our CEO Kristen Fortney recently explored this question on RBC Capital Markets' "Pathfinders in Biopharma" podcast, diving deep into how BioAge is translating






The tremendous success of GLP-1/GIP receptor agonists is rewriting the playbook for metabolic diseases. At #BIO2025, BioAge CEO Kristen Fortney will participate in an expert panel to discuss how the rapidly evolving therapeutic landscape has opened the door for next-generation


"It's like building a roadmap of human aging biology that can show us exactly where and when to intervene." — BioAge COO & co-founder Eric Morgen on the power of large-scale profiling of longitudinal aging data to yield new therapeutic targets. BioAge recently announced an


The future of drug discovery is rooted in human biology—starting with preclinical human models that boost translational success. At #BIO2025, BioAge CEO Kristen Fortney joined the panel “Replacing Guesswork with Data: How Preclinical Human Models Are Driving More Predictive Drug


Proud to share that BioAge presented some of our compelling new preclinical data on APJ agonism at the American Diabetes Association's 85th Scientific Sessions this week. BioAge is advancing next-generation APJ agonists to translate this promising biology into new therapies for obesity and its




